Cytokine-induced killer cell therapy - Boston 3T Biotechnologies
Latest Information Update: 01 Aug 2016
At a glance
- Originator Boston 3T Biotechnologies
- Class Cell therapies
- Mechanism of Action Cytokine induced killer cell modulators; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Aug 2016 Preclinical development is ongoing in USA
- 17 Jan 2014 Preclinical trials in Cancer in USA (unspecified route)